Doc description' Information Disclosure Statement (IDS) Filed

Under the Paperwork Reduction Act of 1995, no persons are required to respo

PTO/SB/05a (07-09)
Approved for use through 07/31/2012 ONS 0651-0201
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unities it contains a valid OMB control number.

INFORMATION DISCLOSUR	ı
STATEMENT BY APPLICAN	1
( Not for submission under 37 CFR 1.99	9

Application Number	Inventor Nakar	10582176					
Filing Date		2007-04-18					
First Named Inventor	Naka	no et al.					
Art Unit		1641					
Examiner Name	Pens	ee T. Do					
Attorney Docket Numi	hor	14875.01631181					

		· ·			U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	Name of Patentee or Applicant of cited Document Pages, Columns, Linguista Relevant Passage; Figures Appear						
	1										
If you wisl	h to a	i dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Name of Patentee or Applicant			Releva		Lines where ges or Relev		
	1										
If you wisl	h to a	dd additional U.S. Publit				,		d button	=		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>					e or	Pages,Columns,Line where Relevant Passages or Relevan Figures Appear		TE	
	1										
If you wis	h to a	ld additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or of	nal, seri	al, symp	osium,	catalog, etc), o					Тs

## | Application Number | 1058/2176 | Filing Date | 2007-04-18 | Filing Date |

1	BORDEN et al., "Lymphokines and Cytokines as Cancer Treatment," Cancer, 65,800-814 (1990)	
2	BYERS, "What Can Randomized Controlled Trials Tell us About Nutrition and Cancer Prevention?," CA Cancer J. Clin., 49:353-361 (1999)	
3	GRANZIERO et al., "Adoptive immunotherapy prevents prostate cancer in a transgenic animal model," Eur. J. Immunol., 29:1127-1138 (1999)	
4	U.S. EXAMINER ELLY GERALD STOKCA, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/913,229, mailed November 3, 2009, 40 pages	

EXAMINER Signature

Date Considered

FEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at <u>work USPTO\_GOV</u> or MPEP 901.64. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPDO Standard STS.). <sup>3</sup> FeD Japanese spartel documents are noticed on the year of the steps of the Emperor must preced be serial number of the plaint document. The patent should be serial number of the plaint document under the proposal respect to the serial number of the plaint document. The patent should be serial number of the plaint document under the Colombia Standard STS displaints. <sup>3</sup> Papentar the Japanese spart of the patent should be serial number of the plaint document under the Colombia Standard STS displaints. <sup>3</sup> Papentar the Japanese spart of the patent should be serial number of the plaint document under the patent should be serial number of the plaint document.